News
VRNA
41.42
+5.50%
2.16
Verona Pharma (VRNA) Gets a Buy from Truist Financial
TipRanks · 3d ago
Weekly Report: what happened at VRNA last week (1202-1206)?
Weekly Report · 4d ago
Insider Sale: President and CEO of $VRNA (VRNA) Sells 162,800 Shares
Barchart · 6d ago
Insider Sale: Chief Financial Officer of $VRNA (VRNA) Sells 12,936 Shares
Barchart · 12/03 04:32
Jefferies Sticks to Their Buy Rating for Verona Pharma (VRNA)
TipRanks · 12/02 13:16
Weekly Report: what happened at VRNA last week (1125-1129)?
Weekly Report · 12/02 10:12
Verona Pharma: In COPD, There's A Corner With Their Name On It
Seeking Alpha · 11/27 14:12
Weekly Report: what happened at VRNA last week (1118-1122)?
Weekly Report · 11/25 10:08
Verona Pharma Announces December 2024 Investor Conference Participation
Barchart · 11/19 01:00
Weekly Report: what happened at VRNA last week (1111-1115)?
Weekly Report · 11/18 10:06
Druckenmiller's Duquesne closes some media holdings, loads into regional banks, among Q3 trades
Seeking Alpha · 11/14 21:24
Truist Financial Issues a Buy Rating on Verona Pharma (VRNA)
TipRanks · 11/13 12:29
Weekly Report: what happened at VRNA last week (1104-1108)?
Weekly Report · 11/11 10:13
Biotech Alert: Searches spiking for these stocks today
TipRanks · 11/07 15:55
Verona Pharma management to meet with BTIG
TipRanks · 11/06 18:15
Verona Pharma Is Maintained at Overweight by Wells Fargo
Dow Jones · 11/05 15:10
Wells Fargo Maintains Overweight on Verona Pharma, Raises Price Target to $64
Benzinga · 11/05 15:02
Verona Pharma Price Target Raised to $42.00/Share From $36.00 by HC Wainwright & Co.
Dow Jones · 11/05 13:42
Verona Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/05 13:42
More
Webull provides a variety of real-time VRNA stock news. You can receive the latest news about Verona Pharma through multiple platforms. This information may help you make smarter investment decisions.
About VRNA
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.